LIHNCS - Lugol’s iodine in head and neck cancer surgery: a multicentre, randomised controlled trial assessing the effectiveness of Lugol’s iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection margins of oral and oropharyngeal squamous cell carcinoma: study protocol for a randomised controlled trial

Table 1 Eligibility criteria

Inclusion criteria	Exclusion criteria
Provision of written informed consent	Previous surgery, chemotherapy or radiotherapy for head and neck cancer
Men and women aged >18 years	Allergy to iodine
Histologically proven squamous cell carcinoma of the oral cavity or oropharynx	Distant metastases (positive neck nodes are not an exclusion)
Planned for primary surgical treatment with curative intent	Nasal, nasopharyngeal or occult primary carcinoma
	Previous diagnosis of cancer in the past 5 years (except basal cell carcinoma or carcinoma of the cervix in situ).

ISSN: 1745-6215